Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 2% of the world's population. In this guideline, we focus the discussion on systemic, nonbiologic medications for the treatment of this disease. We provide detailed discussion of efficacy and safety for the most commonly used medications, including methotrexate, cyclosporine, and acitretin, and provide recommendations to assist prescribers in initiating and managing patients on these treatments. Additionally, we discuss newer therapies, including tofacitinib and apremilast, and briefly touch on a number of other medications, including fumaric acid esters (used outside the United States) and therapies that are no longer widely used for the treatment of psoriasis (ie, hydroxyurea, leflunomide, mycophenolate mofetil, thioguanine, and tacrolimus).

中文翻译：

---

美国皮肤病学会-国家银屑病基金会联合指南，通过全身性非生物疗法治疗银屑病。

牛皮癣是一种慢性炎症性疾病，涉及多个器官系统，约占世界人口的2％。在本指南中，我们将讨论重点放在用于治疗该疾病的全身性非生物药物上。我们详细讨论了最常用的药物（包括甲氨蝶呤，环孢素和阿维A酸）的疗效和安全性，并提供建议以帮助开药者启动和管理这些治疗方法的患者。此外，我们将讨论较新的疗法，包括tofacitinib和apremilast，并简要介绍许多其他药物，包括富马酸酯（在美国以外使用）和不再广泛用于治疗牛皮癣的疗法（例如，羟基脲） ，来氟米特，霉酚酸酯，硫鸟嘌呤，